2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
2cureX AB (“2cureX”) today announces that it together with Scandion Oncology A/S, Copenhagen and Erasmus Medical Centre, Rotterdam has received a grant of 800. 000 EUR from Eurostars. The grant will be used to study if Scandion Oncology’s drug candidate, SCO -101 can overcome resistance to antiestrogen therapy in metastatic breast cancer patients, and if 2cureX’s IndiTreast test can stratify such patients based on SCO-101 sensitivity. Inlägget 2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients dök först upp på IPO.
se.